Monday , October 3 2022

Great news for kids with peanut allergies


/ It contains about 150 mg of peanut protein per peanut kernel.

Share this story

Peanuts allergies are food allergies. Increasing the quantity of peanut proteins can cause serious reactions. For allergy-targeted children, the killer may also be cured, always in tiny doses. The results of clinical trials published in the New England Journal of Medicine show great results with great desensitization. The treatment does not cure allergy, and it involves great risks, but children are able to live their lives without eating any peanut flavor agent.

The principle behind the desensitization or allergic immunotherapy (AIT) is to reduce the exposure of the body to an allergen at low doses and gradually increase when the invader discovers something less. In 2015, the Allergy and Clinical Immunology Magazine published a detailed "international consensus" on the treatment and, as a result of which the childhood controversy was not available, there was not enough food to understand allergies.

Ketal's allergic AIT study was conducted, but it did not provide high-quality evidence for treatment. That's why Phase 3 trial news is great news: the final phase is a must-have for drug trials, as the regulatory bodies like the FDA may request from the authorized drug. However, this does not mean that when this science is done and when everyone goes home, there is a need for a lot of answers, and many times more than one trial is required.

Peanut challenge

This test took 66 countries in one country in 10 countries and enrolled 551 patients with peanut allergy. The majority of these patients (496) were between 4 and 17 years old. All participants took part in a food screening challenge on the same day, a protein protein or flavor-disguised peanut protein was given to them and one second of a second food. The idea was sure that the participants did not know whether eating peanuts or not, and who ate food did not know what they ate. Only a hidden peanut protein was a reaction in the trial.

Afterwards, the participants were randomized: a quarter of a placeholder, treatment that was identical to the treatment, but did not receive peanut protein, three quarters of the treatment. The treatment began with the peanut protein from 0.5 mg in the initial dose, and during 24 weeks, it started to gradually increase on a single 300 mg peanut. Subsequently, it reached the maintenance phase: 300 mg per day for another 24 weeks.

When the treatment was over, the results were very poor. In another food challenge, the researchers demonstrated how they achieved the tolerance of the participants. This began with the small peanut protein, and when the participant took a dose, the dose was increased in the next round. The placebo group performed only eight percent in the 300 mg round compared to 77% of the treatment group.

In the next round of 600 mg, the percentage of four children was performed in the squabbling group and 67% of the treatment group performed. 2.4% of Placebus can contain peanut protein with 1000 mg compared to half of the treatment group. In 55 adult trials, the reactions in food challenge reactions were not statistically significant.

Standing with epiphones

It is very dangerous to light up a large group of children, lighten it, and do not risk it. In this evaluation, there was a high drop-in rate of 12% of group assets due to side effects, and all the participants in the treatment reacted virtually, two-thirds of them moderate or severe. This is probably not entirely attributed to treatment, but it is greater than the rate of the squabbling group; For less than half, there was a moderate or severe incident in the trial.

In the final food challenge, in the treatment group, 5% of the children had a severe reaction and 25% had a moderate reaction. The placebo was much lower than the rate of the group -11 percent and 59 percent respectively- but treatment and testing were significant risks. "This is not something at home," says Michael Perkin, an epidemiologist.

A great deal of jail sentence is a six-month maturation period. Long-term maintenance therapies are underway, but at this stage there is no evidence that the long-term maintenance of the treatment is effective or even more secure. Long-term maintenance requires continuing patient discipline, probably due to other lifestyle, written by Perkin: "The main concerns about immunotherapy that cause allergic tolerance will be temporary and lose if regular consumption is interrupted."

Despite these warnings, there is no doubt that wonderful and good news for kids with peanut allergies. "Parents use very little peanuts to keep their children low at a low price to maintain the potential threat of systemic anaphylaxis for small children," says Perkin.

New England Journal of Medicine, 2018. DOI: ().

Source link